[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100336968":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":39,"centralContacts":43,"locations":48,"responsibleParty":64,"collaborators":24,"id":67,"slug":24,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":24,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":24,"enrollmentInfo":76,"targetDuration":24,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":51,"whyStopped":24,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Columbia University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-Dose Aspirin (LDA) Intervention Group","ACTIVE_COMPARATOR","Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.",[13],"Drug: Aspirin tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Control Group","PLACEBO_COMPARATOR","Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.",[19],"Drug: Placebo oral capsule",{"label":21,"type":22,"description":23,"interventionNames":24},"Healthy Controls Group","NO_INTERVENTION","Subjects who are healthy volunteers (n = 10) without severe preeclampsia prior to delivery.",null,[26,33],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Aspirin tablet","Low dose aspirin, 81mg tablets, PO",[9],[32],"Aspirin",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Placebo oral capsule","Placebo oral capsule, PO",[15],[38],"Placebo",[40],{"name":41,"affiliation":5,"role":42},"Aleha Aziz, MD, MPH","PRINCIPAL_INVESTIGATOR",[44],{"name":41,"role":45,"phone":46,"phoneExt":24,"email":47},"CONTACT","646-678-0289","aa4065@cumc.columbia.edu",[49],{"facility":50,"status":51,"city":52,"state":52,"zip":53,"country":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Columbia University Irving Medical Center","RECRUITING","New York","10032","United States",{"type":56,"coordinates":57},"Point",[58,59],-74.00597,40.71427,{"lat":59,"lon":58},[62,63],{"name":41,"role":45,"phone":46,"phoneExt":24,"email":47},{"name":41,"role":42,"phone":24,"phoneExt":24,"email":24},{"type":42,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Aleha Aziz","Assistant Professor of Obstetrics and Gynecology","100336968",false,"NCT03667326","Postpartum Low-Dose Aspirin and Preeclampsia","Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia","Inclusion Criteria:\n\n* Singleton or Multiple gestation\n* Maternal age \\>= 18 years\n* 20 0\u002F7 weeks gestation or greater\n* Severe Preeclampsia diagnosed prior to delivery\n\nExclusion Criteria:\n\n* Aspirin use postpartum for other medical indication\n* Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)\n* Aspirin use within 7 days of planned initial FMD testing postpartum\n* Hypersensitivity or allergy to Aspirin or other salicylates\n* Hypersensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) - exception if taking LDA in pregnancy\n* Nasal polyps\n* Gastric or Duodenal ulcers, history of GI bleeding\n* Severe hepatic dysfunction\n* Bleeding disorders and diathesis\n* Breastfeeding a newborn with low platelets (NAIT)\n\nFor sub-study patients, inclusion and exclusion criteria will be the same, with the exception of diagnosis of severe preeclampsia prior to delivery (exclusion criterion for healthy controls group).",true,"FEMALE","18 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.",[84],"Preeclampsia Postpartum",[32],"2026-01-21",{"date":88,"type":89},"2026-01-22","ACTUAL",{"date":91,"type":89},"2019-07-22",{"date":93,"type":78},"2026-12",{"name":5,"class":6},1]